Larvol Delta - Viracta-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1b2-Trial-of-Nanaval-in-Patients-with-Advanced-EpsteinBarr-VirusPositive-Solid-Tumors

Valcyte (valganciclovir) - Roche, Mitsubishi Tanabe

Keytruda (pembrolizumab) - Merck (MSD)

nanatinostat (VRx-3996) - Viracta Therap

https://www.prnewswire.com/news-releases/viracta-therapeutics-announces-first-patient-dosed-in-phase-1b2-trial-of-nana-val-in-patients-with-advanced-epstein-barr-virus-positive-solid-tumors-301471307.html

Jan 31, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next